Redmile Group LLC bought a new stake in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 657,356 shares of the medical device company’s stock, valued at approximately $16,480,000. Redmile Group LLC owned approximately 1.00% of NxStage Medical at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in NXTM. Russell Investments Group Ltd. lifted its position in shares of NxStage Medical by 67.9% during the 1st quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock valued at $773,000 after buying an additional 11,668 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of NxStage Medical by 0.5% during the 1st quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock valued at $17,168,000 after buying an additional 2,914 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of NxStage Medical by 148.4% during the 1st quarter. UBS Asset Management Americas Inc. now owns 32,532 shares of the medical device company’s stock valued at $873,000 after buying an additional 19,434 shares in the last quarter. Karp Capital Management Corp purchased a new position in shares of NxStage Medical during the 1st quarter valued at approximately $256,000. Finally, Parametric Portfolio Associates LLC lifted its position in shares of NxStage Medical by 45.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 45,716 shares of the medical device company’s stock valued at $1,227,000 after buying an additional 14,384 shares in the last quarter. Hedge funds and other institutional investors own 92.66% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/08/redmile-group-llc-takes-16-48-million-position-in-nxstage-medical-inc-nxtm.html.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 24,000 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $29.64, for a total transaction of $711,360.00. Following the completion of the sale, the president now directly owns 82,903 shares in the company, valued at $2,457,244.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Joseph E. Turk, Jr. sold 7,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $22.98, for a total value of $160,860.00. Following the sale, the president now owns 82,903 shares of the company’s stock, valued at $1,905,110.94. The disclosure for this sale can be found here. Insiders sold 50,400 shares of company stock valued at $1,406,020 over the last quarter. Insiders own 4.70% of the company’s stock.

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) traded up 0.18% on Friday, hitting $27.68. The stock had a trading volume of 166,024 shares. The firm has a 50 day moving average of $27.87 and a 200 day moving average of $25.85. NxStage Medical, Inc. has a 12 month low of $20.45 and a 12 month high of $30.80. The stock’s market cap is $1.83 billion.

NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The company had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same period in the previous year, the business earned ($0.03) earnings per share. NxStage Medical’s quarterly revenue was up .0% compared to the same quarter last year. On average, equities analysts forecast that NxStage Medical, Inc. will post ($0.05) earnings per share for the current fiscal year.

A number of research analysts have recently issued reports on NXTM shares. Craig Hallum started coverage on NxStage Medical in a research report on Tuesday, June 27th. They set a “buy” rating and a $32.00 target price on the stock. BidaskClub upgraded NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Northland Securities reiterated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Monday, August 7th. Canaccord Genuity lowered NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price on the stock. in a research report on Monday, August 7th. Finally, William Blair lowered NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company. NxStage Medical has a consensus rating of “Hold” and a consensus target price of $30.25.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.